Astrana Health (ASTH) Stock Price, News & Analysis

Company Overview

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.

Key Stats

• Today's Range: $41.99 to $42.85
• 50-Day Range: $40.51 to $62.54
• 52-Week Range: $32.32 to $63.20
• Volume: 280,101 shs
• Average Volume: 320,497 shs
• Market Capitalization: $2.37 billion
• P/E Ratio: 32.39
• Dividend Yield: N/A
• Price Target: $65.17
• Consensus Rating: Buy

Astrana Health Stock Analysis - MarketRank™

Astrana Health scored higher than 80% of companies evaluated by MarketBeat, and ranked 216th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Astrana Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Astrana Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 19.66%

Earnings Growth

Earnings for Astrana Health are expected to grow by 19.66% in the coming year, from $1.17 to $1.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astrana Health is 32.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astrana Health is 32.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.40.

Price to Earnings Growth Ratio

Astrana Health has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Astrana Health has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.23% of the float of Astrana Health has been sold short.

Short Interest Ratio / Days to Cover

Astrana Health has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Astrana Health has recently decreased by 12.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astrana Health does not currently pay a dividend.

Dividend Growth

Astrana Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.23% of the float of Astrana Health has been sold short.

Short Interest Ratio / Days to Cover

Astrana Health has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Astrana Health has recently decreased by 12.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.97

News Sentiment

Astrana Health has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Astrana Health this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Astrana Health to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astrana Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.46% of the stock of Astrana Health is held by insiders.

Percentage Held by Institutions

52.77% of the stock of Astrana Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASTH Stock Analysis - Frequently Asked Questions

How have ASTH shares performed this year?

Astrana Health's stock was trading at $42.79 at the start of the year. Since then, ASTH stock has decreased by 1.6% and is now trading at $42.11.
View the best growth stocks for 2024 here.

How were Astrana Health's earnings last quarter?

Astrana Health, Inc. (NASDAQ:ASTH) announced its quarterly earnings data on Thursday, November, 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The business earned $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a trailing twelve-month return on equity of 9.37% and a net margin of 3.63%.

Who are Astrana Health's major shareholders?

Top institutional shareholders of Astrana Health include State Street Corp (2.82%), Geode Capital Management LLC (1.81%), FMR LLC (1.70%) and SteelPeak Wealth LLC (1.21%).

How do I buy shares of Astrana Health?

Shares of ASTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Astrana Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Astrana Health investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Management consulting services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ASTH
• Previous Symbol: NASDAQ:ASTH
• CUSIP: N/A
• CIK: 1083446
• Web: www.apollomed.net
• Phone: 626-282-0288
• Fax: 818-839-5190
• Employees: 1,800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.17
• High Stock Price Target: $86.00
• Low Stock Price Target: $50.00
• Potential Upside/Downside: +54.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.30
• Trailing P/E Ratio: 32.39
• Forward P/E Ratio: 35.99
• P/E Growth: 1.95
• Net Income: $60.72 million
• Net Margins: 3.63%
• Pretax Margin: 4.86%
• Return on Equity: 9.37%
• Return on Assets: 5.32%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 1.91
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $1.39 billion
• Price / Sales: 1.71
• Cash Flow: $1.36 per share
• Price / Cash Flow: 30.86
• Book Value: $12.61 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 56,250,000
• Free Float: 51,494,000
• Market Cap: $2.37 billion
• Optionable: Optionable
• Beta: 1.24